Harvard Bioscience, Inc. cash flow to debt ratio of 15.20% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Harvard Bioscience, Inc.'s free cash flow has increased -408.01% from $-1.82M last year to $5.62M, signaling increasing performance

Harvard Bioscience, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Harvard Bioscience, Inc.'s debt has decreased relative to shareholder equity from 0.70 last year to 0.00 today, signaling strengthened financials

Harvard Bioscience, Inc. has negative EBITDA, making leverage ratio unreliable

Harvard Bioscience, Inc.'s interest coverage ratio is 0.30, which means that the company struggles to meet interest obligations, signaling financial risk.

Harvard Bioscience, Inc.'s profit margin has increased (-10.02%) in the last year from -13.18% to -11.86%, signaling increasing performance

Harvard Bioscience, Inc.'s short-term assets of $48.23M exceed its short-term liabilities of $21.96M

Harvard Bioscience, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Harvard Bioscience, Inc.'s return on equity of -110.04%, is lower than 15.00%, indicating bad performance

Harvard Bioscience, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Harvard Bioscience, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Harvard Bioscience, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Harvard Bioscience, Inc. has a free cash flow yield of 19.48%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Harvard Bioscience, Inc.'s yearly earnings has decreased 357.07% since last year from $-12.40M to $-56.70M, signaling decreasing performance

Harvard Bioscience, Inc.'s yearly revenue has decreased 8.06% since last year from $94.14M to $86.55M, signaling decreasing performance

ROIC 1.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Harvard Bioscience, Inc.'s 3-year revenue CAGR of -8.60% is negative, indicating declining revenue over the past 3 years

Harvard Bioscience, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Harvard Bioscience, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Harvard Bioscience, Inc. is overvalued relative to its fair value price of 2.73 based on Discounted Cash Flow model

Harvard Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Harvard Bioscience, Inc. is overvalued relative to its fair value price of 0.35 based on EBITDA multiple model

Harvard Bioscience, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Harvard Bioscience, Inc. is overvalued relative to its fair value price of -0.95 based on Earnings Fair Value model

Harvard Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Harvard Bioscience, Inc. has a price-to-book ratio of 0.38x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Harvard Bioscience, Inc. has a price-to-sales ratio of 0.33x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue